The European Cancer Congress has several studies involving the treatment with molecularly targeted drugs represented by gefitinib. I. New treatment options after TKI resistance, switching to chemotherapy, switching to another targeted drug, continuing targeted drug in combination with chemotherapy, switching to third generation targeted drugs, targeted drug in combination with anti-angiogenic drugs, targeted drug in combination with c-MET inhibitors, targeted drug in combination with IGF-IR inhibitors Patients with EGFR-based mutations, even if the tumor appears resistant to TKI drugs, still some cells maintain mutational activity. Therefore, the treatment is recommended to take into account both the cells with acquired resistance and the cells with mutation activity. The sensitivity of plasma specimens for detection of EGFR mutations is 66% and the specificity is 100%. The benefit of TKI reuse in patients with brain metastases is significant for patients who have failed previous TKI therapy, where the use of TKI drugs still has some efficacy for patients with intracranial brain metastases, especially for patients with brain metastases that appeared during the initial targeted drug therapy. Fourth, the TKI treatment for wild-type patients was revisited in a number of second-line treatment clinical studies, most of which showed that in EGFR wild-type patients, the progression-free survival time of patients called chemotherapy was significantly shortened, but there was no difference in survival, which suggests that EGFR-TKI drugs still have a role in prolonging survival time for wild-type patients. V. Tumor-related symptom improvement can be used as a predictive marker for targeted drug efficacy In the absence of access to patient information on EGFR mutations, patients’ clinical symptoms may be a better predictor.